ClinicalTrials.gg
CompletedNCT01281306Updated Jan 29, 2016Results posted

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

A Phase 2 interventional study of LCZ696 and Valsartan in Systolic Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 90 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
910
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Isolated Systolic Hypertension with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Isolated Systolic Hypertension · United States.

Enrollment
Largest of 12
910 · median 145
Started
2011
with 1 other
Phase 2
3 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
2 of 13
Novartis Pharmaceuticals

Among the 13 studies in Isolated Systolic Hypertension with a site in United States, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 7th registered.

Isolated Systolic Hypertension

35 studies on the registry are indexed under Isolated Systolic Hypertension; 8 are open to participants now.

Browse Isolated Systolic Hypertension studies →

Open to participants now

3 of the 13 studies in Isolated Systolic Hypertension with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Isolated Systolic Hypertension studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Isolated Systolic Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).

03

Conditions studied

  • Systolic Hypertension

Keywords

  • hypertension
  • blood pressure
  • LCZ696
  • dual-acting
  • neprilysin
  • nep inhibitor
  • vasopeptidase
  • angiotensin receptor
  • angiotensin receptor neprilysin inhibitor (ARNi)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed. Patients with mild-to-moderate systolic hypertension, untreated or currently taking antihypertensive therapy.
  • Ability to communicate and comply with all study requirements and demonstrate good medication compliance (≥ 80% compliance rate) during the run-in period.

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • History of angioedema, drug-related or otherwise, as reported by the patient.
  • Pregnant or nursing (lactating) women.
  • Women of (WOCBP), UNLESS they are using adequate methods.
  • History or evidence of a secondary form of hypertension.
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
910 participants (actual)

Study arms

  • Experimental
    VAL + AHU 400 mg

    Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.

    Drug: Valsartan · Drug: AHU377

  • Experimental
    VAL + AHU 200 mg

    Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.

    Drug: Valsartan · Drug: AHU377

  • Experimental
    VAL + AHU 100 mg

    Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.

    Drug: Valsartan · Drug: AHU377

  • Experimental
    VAL + AHU 50 mg

    Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.

    Drug: Valsartan · Drug: AHU377

  • Experimental
    VAL 320 mg

    Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.

    Drug: Valsartan

  • Experimental
    LCZ 400 mg

    Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.

    Drug: LCZ696

  • Experimental
    Placebo

    Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.

    Drug: Placebo

Interventions

  • DrugLCZ696

    LCZ696 was supplied as tablets in blister cards in 100 mg strengths.

  • Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

  • DrugAHU377

    AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.

  • DrugPlacebo

    Placebo was supplied as tablets in blister cards.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

    Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

Secondary outcomes

  1. Change From Baseline in Mean Diastolic Blood Pressure (msDBP)

    Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  2. Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)

    Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  3. Change From Baseline in Daytime maSBP and maDBP

    Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  4. Change From Baseline in Nighttime maSBP and maDBP

    Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

    Time frame: Baseline and 8 weeks

  5. Change From Baseline in Mean Sitting Pulse Pressure

    Pulse rate measurements were performed. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  6. Change From Baseline in Mean Ambulatory Pulse Pressure

    Pulse rate measurements were performed. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  7. Change From Baseline in maSBP and maDBP in Dippers

    Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  8. Change From Baseline in maSBP and maDBP in Non-dippers

    Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  9. Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age

    Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  10. Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age

    Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  11. Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age

    Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  12. Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age

    Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

    Time frame: Baseline, 8 weeks

  13. Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response

    Sitting BP measurements were performed at trough (23-26 hours post-morning dose). Blood pressure control was defined as msSBP/MSDBP \< 140/90 mmHg. Blood pressure response in msSBP was defined as \<140 mmHg or a reduction \>= 20mmHg from baseline. Blood pressure response in msDBP was defined as \< 90 mmHg or a reduction \>= 10 mmHg from baseline.

    Time frame: 8 weeks

  14. Number of Participants With Adverse Events, Serious Adverse Events and Death

    Adverse event monitoring was conducted throughout the study.

    Time frame: 8 weeks

07

Results

Posted Aug 18, 2015

Participant flow

This study consisted of a single-blind run-in period and a double-blind (DB) period. During the 3 to 4 week run-in, participants were assessed for randomization eligibility into the DB period. 910 participants randomized. 3 participants were mis-randomized and did not receive study treatment. Therefore, the participant flow shows 907 participants.

Participant flow — Overall Study
MilestoneVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Started14414514113414314258
Full analysis set14314514113314314258
Safety set14314514113314314258
Ambulatory blood pressure monitoring set95999295939135
Completed13614113312313413551
Not completed84811977
Withdrew: Lack of efficacy0130201
Withdrew: Withdrawal by subject1024131
Withdrew: Protocol deviation0111100
Withdrew: Condition no longer requires study drug1000011
Withdrew: Lost to follow-up1002001
Withdrew: Death1000000
Withdrew: Adverse event3223533
Withdrew: Randomized in error1001000

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)-20.89 ± 1.22-23.55 ± 1.21-21.26 ± 1.23-19.31 ± 1.27-16.13 ± 1.22-21.78 ± 1.22-6.99 ± 1.92
SecondaryChange From Baseline in Mean Diastolic Blood Pressure (msDBP)

Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Diastolic Blood Pressure (msDBP)
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Change From Baseline in Mean Diastolic Blood Pressure (msDBP)-8.47 ± 0.76-9.76 ± 0.75-8.04 ± 0.76-7.15 ± 0.79-7.28 ± 0.76-9.61 ± 0.75-3.38 ± 1.19
SecondaryChange From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)

Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-12.14 ± 0.71-15.66 ± 0.69-14.33 ± 0.72-11.36 ± 0.70-9.59 ± 0.71-12.98 ± 0.71-2.12 ± 1.15
maDBP-5.81 ± 0.44-7.03 ± 0.42-6.46 ± 0.44-5.36 ± 0.43-5.23 ± 0.44-6.20 ± 0.44-0.79 ± 0.71
SecondaryChange From Baseline in Daytime maSBP and maDBP

Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime maSBP and maDBP
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-12.62 ± 1.21-15.85 ± 1.19-14.43 ± 1.23-11.50 ± 1.21-9.60 ± 1.22-13.32 ± 1.23-2.39 ± 1.98
maDBP-5.93 ± 0.77-7.13 ± 0.75-6.57 ± 0.78-5.39 ± 0.77-5.40 ± 0.77-6.16 ± 0.78-0.98 ± 1.26
SecondaryChange From Baseline in Nighttime maSBP and maDBP

Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

Time frame:
Baseline and 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Nighttime maSBP and maDBP
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-11.57 ± 1.23-15.27 ± 1.19-14.74 ± 1.23-10.80 ± 1.21-8.88 ± 1.22-12.34 ± 1.23-1.36 ± 1.98
maDBP-5.27 ± 0.78-6.79 ± 0.75-6.45 ± 0.78-5.27 ± 0.77-4.49 ± 0.77-6.36 ± 0.78-0.22 ± 1.26
SecondaryChange From Baseline in Mean Sitting Pulse Pressure

Pulse rate measurements were performed. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Sitting Pulse Pressure
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Change From Baseline in Mean Sitting Pulse Pressure-12.39 ± 0.91-13.91 ± 0.90-13.18 ± 0.91-12.01 ± 0.95-8.80 ± 0.91-12.18 ± 0.91-3.74 ± 1.43
SecondaryChange From Baseline in Mean Ambulatory Pulse Pressure

Pulse rate measurements were performed. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Ambulatory Pulse Pressure
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Change From Baseline in Mean Ambulatory Pulse Pressure-6.23 ± 0.39-8.51 ± 0.38-7.71 ± 0.40-6.00 ± 0.39-4.40 ± 0.39-6.84 ± 0.39-1.09 ± 0.63
SecondaryChange From Baseline in maSBP and maDBP in Dippers

Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in maSBP and maDBP in Dippers
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-11.43 ± 1.12-15.59 ± 1.00-12.04 ± 1.0510.60 ± 1.01-9.85 ± 1.03-13.09 ± 1.05-2.39 ± 1.45
maDBP-4.62 ± 0.70-7.33 ± 0.62-5.49 ± 0.65-5.07 ± 0.63-5.53 ± 0.64-6.03 ± 0.65-0.98 ± 0.90
SecondaryChange From Baseline in maSBP and maDBP in Non-dippers

Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in maSBP and maDBP in Non-dippers
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-12.81 ± 0.91-16.08 ± 0.94-16.37 ± 0.97-12.17 ± 0.99-9.73 ± 0.96-13.12 ± 0.96-1.46 ± 1.75
maDBP-6.65 ± 0.56-6.91 ± 0.58-7.31 ± 0.60-5.79 ± 0.61-5.10 ± 0.59-6.34 ± 0.59-0.49 ± 1.08
SecondaryChange From Baseline in msSBP and msDBP in Participants < 65 Years of Age

Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
msSBP-20.95 ± 1.68-24.45 ± 1.67-20.94 ± 1.63-18.09 ± 1.79-16.96 ± 1.71-21.06 ± 1.63-8.94 ± 2.73
msDBP-8.97 ± 1.11-10.94 ± 1.11-8.83 ± 1.09-8.07 ± 1.19-6.93 ± 1.13-10.25 ± 1.08-5.19 ± 1.82
SecondaryChange From Baseline in msSBP and msDBP in Participants >= 65 Years of Age

Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
msSBP-20.93 ± 1.79-22.66 ± 1.76-21.72 ± 1.85-20.64 ± 1.81-15.48 ± 1.75-22.83 ± 1.84-5.10 ± 2.71
msDBP-7.89 ± 1.02-8.44 ± 1.00-7.06 ± 1.05-6.17 ± 1.03-7.62 ± 0.99-8.89 ± 1.04-1.46 ± 1.54
SecondaryChange From Baseline in maSBP and maDBP in Participants < 65 Years of Age

Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-12.16 ± 0.98-15.06 ± 0.91-14.42 ± 0.95-10.39 ± 0.95-9.55 ± 0.99-13.98 ± 0.93-2.24 ± 1.67
maDBP-6.74 ± 0.67-7.81 ± 0.62-7.93 ± 0.65-5.69 ± 0.65-5.94 ± 0.67-7.32 ± 0.63-1.53 ± 1.14
SecondaryChange From Baseline in maSBP and maDBP in Participants >= 65 Years of Age

Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age
mmHgVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
maSBP-12.10 ± 1.04-16.08 ± 1.03-14.20 ± 1.08-12.25 ± 1.04-9.73 ± 1.02-11.88 ± 1.10-1.95 ± 1.59
maDBP-4.94 ± 0.58-6.00 ± 0.57-4.86 ± 0.60-4.93 ± 0.58-4.58 ± 0.56-5.04 ± 0.61-0.01 ± 0.88
SecondaryNumber of Participants Who Achieved Blood Pressure Control and Blood Pressure Response

Sitting BP measurements were performed at trough (23-26 hours post-morning dose). Blood pressure control was defined as msSBP/MSDBP \< 140/90 mmHg. Blood pressure response in msSBP was defined as \<140 mmHg or a reduction \>= 20mmHg from baseline. Blood pressure response in msDBP was defined as \< 90 mmHg or a reduction \>= 10 mmHg from baseline.

Time frame:
8 weeks
Reported as:
Number · Number of participants
Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response
Number of participantsVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Blood pressure control7286715857768
msSBP response881019381729411
msDBP response11212611410111111839
SecondaryNumber of Participants With Adverse Events, Serious Adverse Events and Death

Adverse event monitoring was conducted throughout the study.

Time frame:
8 weeks
Reported as:
Number · Number of participants
Number of Participants With Adverse Events, Serious Adverse Events and Death
Number of participantsVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Adverse events (non-serious and serious)40312925384220
Serious adverse events3110111
Deaths1000000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VAL + AHU 400 mg—3/143 (2.1%)1/143 (0.7%)
VAL + AHU 200 mg—1/145 (0.7%)2/145 (1.4%)
VAL + AHU 100 mg—1/141 (0.7%)1/141 (0.7%)
VAL + AHU 50 mg—0/133 (0%)2/133 (1.5%)
VAL 320 mg—1/143 (0.7%)4/143 (2.8%)
LCZ 400 mg—1/142 (0.7%)1/142 (0.7%)
Placebo—1/58 (1.7%)3/58 (5.2%)
Most frequent serious events
Most frequent serious events
EventVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
Calculus urinaryRenal and urinary disorders0/1430/1450/1410/1330/1430/1421/58
Postoperative wound infectionInfections and infestations0/1430/1451/1410/1330/1430/1420/58
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1430/1450/1410/1330/1431/1420/58
Sudden deathGeneral disorders1/1430/1450/1410/1330/1430/1420/58
CholelithiasisHepatobiliary disorders1/1430/1450/1410/1330/1430/1420/58
Thoracic vertebral fractureInjury, poisoning and procedural complications0/1430/1450/1410/1331/1430/1420/58
AngioedemaSkin and subcutaneous tissue disorders1/1430/1450/1410/1330/1430/1420/58
SchizophreniaPsychiatric disorders0/1431/1450/1410/1330/1430/1420/58
Most frequent other events
Most frequent other events
EventVAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlacebo
DyspepsiaGastrointestinal disorders1/1432/1451/1412/1334/1431/1423/58

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlaceboTotal
Mean61.7 ± 11.3661.7 ± 11.4461.0 ± 11.0362.0 ± 10.7362.0 ± 11.4561.2 ± 10.6060.8 ± 11.8161.5 ± 11.13
Sex: Female, Male
Sex: Female, Male(Participants)VAL + AHU 400 mgVAL + AHU 200 mgVAL + AHU 100 mgVAL + AHU 50 mgVAL 320 mgLCZ 400 mgPlaceboTotal
Female78605361607129412
Male66858873837129495
08

Study locations

90 sites
  • Novartis Investigative Site
    Clearwater, Florida 33756, United States
  • Novartis Investigative Site
    Chicago, Illinois 60607, United States
  • Novartis Investigative Site
    Chicago, Illinois 60610, United States
  • Novartis Investigative Site
    Metairie, Louisiana 70006, United States
  • Novartis Investigative Site
    Belzoni, Mississippi 39038, United States
  • Novartis Investigative Site
    Jackson, Mississippi 39202, United States
  • Novartis Investigative Site
    Jackson, Mississippi 39209, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63031, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Henderson, Nevada 89014, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89119, United States
  • Novartis Investigative Site
    Buffalo, New York 14215, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28277, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27401, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27408, United States
  • Novartis Investigative Site
    Shelby, North Carolina 28152, United States
  • Novartis Investigative Site
    Erie, Pennsylvania 16509, United States
  • Novartis Investigative Site
    Bryan, Texas 77802, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1440AAD, Argentina
  • Novartis Investigative Site
    Lanus, Buenos Aires B8000XAV, Argentina
  • Novartis Investigative Site
    Caba, Capital Federal C1179AAB, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000AII, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S200CXP, Argentina
  • Novartis Investigative Site
    San Miguel de Tucuman, Tucuman T4000EBR, Argentina
  • Novartis Investigative Site
    Buenos aires, C1120AAC, Argentina
  • Novartis Investigative Site
    Cordoba, X5003DCP, Argentina
  • Novartis Investigative Site
    Corrientes, W3400, Argentina
  • Novartis Investigative Site
    Mount Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • Novartis Investigative Site
    Mirabel, Quebec J7J 2K8, Canada
  • Novartis Investigative Site
    Ste-Foy, Quebec G1V 4G2, Canada
  • Novartis Investigative Site
    Budapest, 1045, Hungary
  • Novartis Investigative Site
    Budapest, 1136, Hungary
  • Novartis Investigative Site
    Csongrad, 6640, Hungary
  • Novartis Investigative Site
    Erd, H-2030, Hungary
  • Novartis Investigative Site
    Miskolc, 3525, Hungary
  • Novartis Investigative Site
    Miskolc, 3530, Hungary
  • Novartis Investigative Site
    Nyiregyháza, 4400, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Torokbalint, 2045, Hungary
  • Novartis Investigative Site
    Vishakhapatnam, Andhra Pradesh 530002, India
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380 051, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422 005, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422005, India
  • Novartis Investigative Site
    Pune, Maharashtra 411005, India
  • Novartis Investigative Site
    Ludhiana, Punjab 141002, India
  • Novartis Investigative Site
    Jaipur, Rajasthan 302016, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226003, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226005, India
  • Novartis Investigative Site
    Bucheon, Gyeonggi-do 424-717, Korea, Republic of
  • Novartis Investigative Site
    Goyang, Gyeonggi-do 411-706, Korea, Republic of
  • Novartis Investigative Site
    Uijeongbu-Si, Gyeonggi-do 480-717, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 137-701, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 152-703, Korea, Republic of
  • Novartis Investigative Site
    Koyang, Kyunggi 410-719, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 140-743, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 150-713, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 150-950, Korea, Republic of
  • Novartis Investigative Site
    Bucharest, District 1 011422, Romania
  • Novartis Investigative Site
    Bucharest, District 1 012064, Romania
  • Novartis Investigative Site
    Bucharest, District 1, Romania
  • Novartis Investigative Site
    Bucharest, District 2 021705, Romania
  • Novartis Investigative Site
    Oradea, Jud. Bihor 410032, Romania
  • Novartis Investigative Site
    Craiova, Jud. Dolj 200147, Romania
  • Novartis Investigative Site
    Bucharest, 060011, Romania
  • Novartis Investigative Site
    Nitra, Slovak Republic 949 01, Slovakia
  • Novartis Investigative Site
    Presov, Slovak Republic 08001, Slovakia
  • Novartis Investigative Site
    Bratislava, 831 06, Slovakia
  • Novartis Investigative Site
    Liptovsky Mikulas, 031 01, Slovakia
  • Novartis Investigative Site
    Nitra, 949 01, Slovakia
  • Novartis Investigative Site
    Nitra, 94901, Slovakia
  • Novartis Investigative Site
    Nove Zamky, 940 01, Slovakia
  • Novartis Investigative Site
    Partizanske, 958 01, Slovakia
  • Novartis Investigative Site
    Presov, 080 01, Slovakia
  • Novartis Investigative Site
    Presov, 081 01, Slovakia
  • Novartis Investigative Site
    Ruzomberok, 034 26, Slovakia
  • Novartis Investigative Site
    Sala, 927 03, Slovakia
  • Novartis Investigative Site
    Sered, 926 00, Slovakia
  • Novartis Investigative Site
    Zvolen, 960 01, Slovakia
  • Novartis Investigative Site
    Granada, Andalucia 18012, Spain
  • Novartis Investigative Site
    Sevilla, Andalucia 41009, Spain
  • Novartis Investigative Site
    Badalona, Cataluña 08914, Spain
  • Novartis Investigative Site
    Centelles, Cataluña 08540, Spain
  • Novartis Investigative Site
    Tarragona, Cataluña 43350, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03004, Spain
  • Novartis Investigative Site
    Alzira, Comunidad Valenciana 46600, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Barcelona, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 3 years 8 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2011
First posted
Jan 21, 2011
Start
Jan 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results delay requested
Jan 2, 2013
Results first posted
Aug 18, 2015
Last update
Jan 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01281306
Responsible party
Sponsor
First posted
Jan 21, 2011
Start date
Jan 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Aug 18, 2015
Last update
Jan 29, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Sacubitril

Start the discussion